Home › Calculator › SNGX Dividend Calculator 2026
SNGX Dividend DRIP Calculator 2026
512.82% YieldHealthcareSoligenix, Inc. · NASDAQ
Price: $0.39 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When SNGX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your SNGX snowball 📈
$10,000 in SNGX → $5345639711969876992.00M in 10 years · $445,385,161,440,379,500,000,000.00/month
About Soligenix, Inc. (SNGX) — Dividend Analysis 2026
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
Compare SNGX with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full SNGX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SNGX position with:
🌍 SNGX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SNGX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 512.82% | 510.02% | $51,282 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 435.90% | 433.10% | $43,590 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 410.26% | 407.46% | $41,026 / yr |
| 🇬🇧 UK ISA | 0% | 512.82% | 510.02% | $51,282 / yr |
| 🇬🇧 UK Taxable | 8.75% | 467.95% | 465.15% | $46,795 / yr |
| 🇨🇦 TFSA | 0% | 512.82% | 510.02% | $51,282 / yr |
| 🇨🇦 CA Taxable | 25% | 384.62% | 381.81% | $38,462 / yr |
| 🇦🇺 Super (pension) | 15% | 435.90% | 433.10% | $43,590 / yr |
| 🇦🇺 AU Taxable | 30% | 358.97% | 356.17% | $35,897 / yr |
| 🇩🇪 DE Taxable | 26.375% | 377.56% | 374.76% | $37,756 / yr |
| 🇫🇷 FR Taxable | 30% | 358.97% | 356.17% | $35,897 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SNGX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SNGX Dividend Payment Schedule
SNGX pays quarterly — 4 times per year. Next ex-div: TBD.
📊 SNGX vs Healthcare Benchmarks
How SNGX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SNGX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SNGX Insider Activity
No recent SEC filings reported in the last 90 days.Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SNGX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Soligenix, Inc. (SNGX) is currently trading at $0.39, 100% below its 52-week high. The current dividend yield is 512.82% based on an annual payout of $2.00 per share.
SNGX (Soligenix, Inc.) — 512.82% Dividend Yield Analysis
Soligenix, Inc. (SNGX) is a healthcare stock currently trading at $0.39 with a dividend yield of 512.82%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (512.82%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.